- Home
- MOGU vs BLRX Comparison
MOGU vs BLRX Comparison
Compare MOGU & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOGU
- BLRX
- Stock Information
- Founded
- MOGU 2011
- BLRX 2003
- Country
- MOGU China
- BLRX Israel
- Employees
- MOGU N/A
- BLRX N/A
- Industry
- MOGU Business Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MOGU Consumer Discretionary
- BLRX Health Care
- Exchange
- MOGU Nasdaq
- BLRX Nasdaq
- Market Cap
- MOGU 17.8M
- BLRX 15.3M
- IPO Year
- MOGU 2018
- BLRX 2011
- Fundamental
- Price
- MOGU $2.18
- BLRX $4.45
- Analyst Decision
- MOGU
- BLRX Strong Buy
- Analyst Count
- MOGU 0
- BLRX 2
- Target Price
- MOGU N/A
- BLRX $19.00
- AVG Volume (30 Days)
- MOGU 3.5K
- BLRX 2.1M
- Earning Date
- MOGU 07-08-2025
- BLRX 08-14-2025
- Dividend Yield
- MOGU N/A
- BLRX N/A
- EPS Growth
- MOGU N/A
- BLRX N/A
- EPS
- MOGU N/A
- BLRX N/A
- Revenue
- MOGU $19,801,126.00
- BLRX $22,340,000.00
- Revenue This Year
- MOGU N/A
- BLRX N/A
- Revenue Next Year
- MOGU N/A
- BLRX N/A
- P/E Ratio
- MOGU N/A
- BLRX N/A
- Revenue Growth
- MOGU N/A
- BLRX 91.68
- 52 Week Low
- MOGU $1.81
- BLRX $2.30
- 52 Week High
- MOGU $3.14
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- MOGU 52.62
- BLRX 50.17
- Support Level
- MOGU $2.05
- BLRX $3.79
- Resistance Level
- MOGU $2.17
- BLRX $4.62
- Average True Range (ATR)
- MOGU 0.05
- BLRX 0.56
- MACD
- MOGU 0.01
- BLRX -0.13
- Stochastic Oscillator
- MOGU 92.86
- BLRX 21.79
About MOGU MOGU Inc. (each representing 25)
MOGU Inc is an online fashion and lifestyle destination in China. The company's online platform includes Mogu.com, Mogujie.com, and Meilishuo.com. Its platform allows people to discover and share fashion trends while fully enjoying the shopping experience. The company on its platform provides content related to fashion and lifestyle guides in various multi-media formats which include Live Video Broadcasts, Short-form Videos, Photography, and Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology and other relevant services to merchants and users as well as technology services to brands owners.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.